Optimising HbA1c monitoring intervals in patients with type 2 diabetes based on glycaemic control status: a target trial emulation study
For T2DM patients with HbA1<i>c</i><7%, monitoring can be extended to 1.5-2 years. For those with HbA1c 7.0-7.9% and≥8%, recommended intervals are six and three months, respectively. (293 words).
Authors
- Celine Sze Ling Chui (ORCID: https://orcid.org/0000-0003-1513-8726)
- Cindy Lo Kuen Lam (ORCID: https://orcid.org/0000-0001-7536-8481)
- Eric Yuk Fai Wan (ORCID: https://orcid.org/0000-0002-6275-1147)
- Shugang Li (ORCID: https://orcid.org/0000-0002-9835-4012)
- Boyuan Wang (ORCID: https://orcid.org/0000-0003-1854-6178)
- Hao Wu (ORCID: https://orcid.org/0000-0001-9552-3178)
- Emily Tsui Yee Tse
Institutions
- Chinese University of Hong Kong (HK)
- Capital Medical University (CN)
- Li Ka Shing Foundation (CN)
- Hong Kong Science and Technology Parks Corporation (HK)
- Centre of Excellence for Advanced Materials (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- HKU-Pasteur Research Pole (HK)
- University of Hong Kong (HK)
Publication Details
- Journal
- BJGP Open
- Published
- 2025-11-03
- DOI
- https://doi.org/10.3399/bjgpo.2025.0020
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 0.00